Characterization of the Bacteriophage-Derived Endolysins PlySs2 and PlySs9 with In Vitro Lytic Activity against Bovine Mastitis .

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
TitleCharacterization of the Bacteriophage-Derived Endolysins PlySs2 and PlySs9 with In Vitro Lytic Activity against Bovine Mastitis .
Publication TypeJournal Article
Year of Publication2020
AuthorsElst, NVander, Linden, SB, Lavigne, R, Meyer, E, Briers, Y, Nelson, DC
JournalAntibiotics (Basel)
Volume9
Issue9
Date Published2020 Sep 19
ISSN2079-6382
Abstract

Bovine mastitis, an infection of the cow's mammary gland, is frequently caused by and causes major economic losses in the dairy industry. The intramammary administration of antibiotics currently remains the predominant preventive and therapeutic measure. These antimicrobial compounds, of which some are considered critical in human health care, are frequently applied as dry therapy resulting in their consistent overuse. Therefore, the use of antibiotics in the dairy sector is being questioned. We here identified two endolysins, i.e., PlySs2 and PlySs9, respectively derived from serotype-2 and -9 prophages, with lytic activity against in an in vitro setting. Both endolysins gave clear lysis zones in spot-on-plate assays and caused a reduction of the optical density in a turbidity reduction assay. In depth characterization identified PlySs9 as the more potent endolysin over PlySs2 with a lower MIC value and about one additional log of killing. PlySs2 and PlySs9 were challenged to a panel of subclinical and clinical milk isolates and were both able to lyse all strains tested. Molecular dissection of these endolysins in catalytic and cell wall binding subdomains resulted in major loss of killing and binding activity, respectively. Taken together, we here propose PlySs2 and PlySs9 as candidate compounds to the current antimicrobial arsenal known against bovine mastitis-causing as future add-on or replacement strategy to the currently used intramammary antibiotics.

DOI10.3390/antibiotics9090621
Alternate JournalAntibiotics (Basel)
PubMed ID32961696
Grant List1.S.236.20N / / Fonds Wetenschappelijk Onderzoek /
Doctoral research grant for Niels Vander Elst (no grant number available) / / Belgian American Educational Foundation /